JP2023540904A - タンパク質および核酸をアッセイするための組成物および方法 - Google Patents

タンパク質および核酸をアッセイするための組成物および方法 Download PDF

Info

Publication number
JP2023540904A
JP2023540904A JP2023513345A JP2023513345A JP2023540904A JP 2023540904 A JP2023540904 A JP 2023540904A JP 2023513345 A JP2023513345 A JP 2023513345A JP 2023513345 A JP2023513345 A JP 2023513345A JP 2023540904 A JP2023540904 A JP 2023540904A
Authority
JP
Japan
Prior art keywords
proteins
particles
biological sample
protein
nanoparticles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023513345A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023540904A5 (enExample
Inventor
ダニエル ホーンバーグ，
マイケル フィガ，
シャオヤン ジャオ，
アシム エス． シディキ，
フィリップ マ，
サンテ キム，
オミッド シー． ファロクザド，
マーガレット ドノヴァン，
ジョン イー． ブルーム，
セオドア プラット，
マーティン ゴールドバーグ，
ダミアン ハリス，
Original Assignee
シアー， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シアー， インコーポレイテッド filed Critical シアー， インコーポレイテッド
Publication of JP2023540904A publication Critical patent/JP2023540904A/ja
Publication of JP2023540904A5 publication Critical patent/JP2023540904A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326—Magnetic particles
    • G01N33/54333—Modification of conditions of immunological binding reaction, e.g. use of more than one type of particle, use of chemical agents to improve binding, choice of incubation time or application of magnetic field during binding reaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/40—Concentrating samples
    • G01N1/405—Concentrating samples by adsorption or absorption
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2531/00—Reactions of nucleic acids characterised by
    • C12Q2531/10—Reactions of nucleic acids characterised by the purpose being amplify/increase the copy number of target nucleic acid
    • C12Q2531/113—PCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2535/00—Reactions characterised by the assay type for determining the identity of a nucleotide base or a sequence of oligonucleotides
    • C12Q2535/122—Massive parallel sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
    • C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
    • C12Q2537/159—Reduction of complexity, e.g. amplification of subsets, removing duplicated genomic regions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Peptides Or Proteins (AREA)
  • Nanotechnology (AREA)
JP2023513345A 2020-08-25 2021-08-24 タンパク質および核酸をアッセイするための組成物および方法 Pending JP2023540904A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202063070205P 2020-08-25 2020-08-25
US63/070,205 2020-08-25
US202063112071P 2020-11-10 2020-11-10
US63/112,071 2020-11-10
US202163143738P 2021-01-29 2021-01-29
US63/143,738 2021-01-29
US202163166173P 2021-03-25 2021-03-25
US63/166,173 2021-03-25
US202163194612P 2021-05-28 2021-05-28
US63/194,612 2021-05-28
PCT/US2021/047397 WO2022046804A2 (en) 2020-08-25 2021-08-24 Compositions and methods for assaying proteins and nucleic acids

Publications (2)

Publication Number Publication Date
JP2023540904A true JP2023540904A (ja) 2023-09-27
JP2023540904A5 JP2023540904A5 (enExample) 2024-09-03

Family

ID=80355675

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023513345A Pending JP2023540904A (ja) 2020-08-25 2021-08-24 タンパク質および核酸をアッセイするための組成物および方法

Country Status (10)

Country Link
US (2) US12276668B2 (enExample)
EP (1) EP4204580A4 (enExample)
JP (1) JP2023540904A (enExample)
KR (1) KR20230079044A (enExample)
CN (1) CN116529393A (enExample)
AU (1) AU2021333661A1 (enExample)
CA (1) CA3190719A1 (enExample)
DE (1) DE112021004478T5 (enExample)
IL (1) IL300826A (enExample)
WO (1) WO2022046804A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019374692B2 (en) 2018-11-07 2025-08-28 Seer, Inc. Compositions, methods and systems for protein corona analysis and uses thereof
JP7518852B2 (ja) 2019-03-26 2024-07-18 シアー， インコーポレイテッド 生物流体からのタンパク質コロナ分析のための組成物、方法およびシステム、ならびにそれらの使用
GB2606810A (en) 2019-08-05 2022-11-23 Seer Inc Systems and methods for sample preparation, data generation, and protein corona analysis
WO2021087407A1 (en) * 2019-11-02 2021-05-06 Seer, Inc. Systems for protein corona analysis
DE112021004478T5 (de) 2020-08-25 2023-09-14 Seer, Inc. Zusammensetzungen und verfahren zur bestimmung von proteinen und nukleinsäuren
CN114854859A (zh) * 2022-05-05 2022-08-05 四川省肿瘤医院 一种基于血小板内FlnA基因表达量的肺结节良恶性诊断方法
IL317700A (en) * 2022-06-15 2025-02-01 Seer Inc Systems and methods for testing biomolecules
EP4551947A1 (en) * 2022-07-08 2025-05-14 Seer, Inc. Methods for analyzing biological samples
WO2025184649A1 (en) * 2024-03-01 2025-09-04 University Of South Florida Methods of inhibiting m6a reader ythdf1 for treating neurodegenerative disease
WO2026072550A1 (en) * 2024-09-27 2026-04-02 Abbott Rapid Diagnostics International Unlimited Company Methods and compositions for freeze drying paramagnetic particles
TWI921285B (zh) * 2025-09-18 2026-04-01 國立中興大學 牛乳的單一產地與非單一產地的混乳辨識方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020096631A2 (en) * 2018-11-07 2020-05-14 Seer, Inc. Compositions, methods and systems for protein corona analysis and uses thereof

Family Cites Families (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863873A (en) 1980-01-14 1989-09-05 Esa, Inc. Method for biological testing and/or developing pharmaceuticals for treatment of disorders
US4444879A (en) 1981-01-29 1984-04-24 Science Research Center, Inc. Immunoassay with article having support film and immunological counterpart of analyte
CA1340966C (en) 1989-05-19 2000-04-18 Thomas R. Covey Method of protein analysis
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5366140A (en) 1993-09-30 1994-11-22 Minnesota Mining And Manufacturing Company Patterned array of uniform metal microbeads
US5498545A (en) 1994-07-21 1996-03-12 Vestal; Marvin L. Mass spectrometer system and method for matrix-assisted laser desorption measurements
US6361944B1 (en) 1996-07-29 2002-03-26 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US5900481A (en) 1996-11-06 1999-05-04 Sequenom, Inc. Bead linkers for immobilizing nucleic acids to solid supports
US6327410B1 (en) 1997-03-14 2001-12-04 The Trustees Of Tufts College Target analyte sensors utilizing Microspheres
US5928952A (en) 1997-11-05 1999-07-27 Zymark Corporation Scheduled system and method for processing chemical products
US6413780B1 (en) 1998-10-14 2002-07-02 Abbott Laboratories Structure and method for performing a determination of an item of interest in a sample
ATE444481T1 (de) 1998-11-16 2009-10-15 California Inst Of Techn Gleichzeitige bestimmung von gleichgewichts- und kinetischen eigenschaften
DE19852928C1 (de) 1998-11-17 2000-08-03 Steffen Panzner Strukturen in Form von Hohlkugeln
US20020009394A1 (en) 1999-04-02 2002-01-24 Hubert Koster Automated process line
US8080380B2 (en) 1999-05-21 2011-12-20 Illumina, Inc. Use of microfluidic systems in the detection of target analytes using microsphere arrays
US6969615B2 (en) 1999-07-26 2005-11-29 20/20 Genesystems, Inc. Methods, devices, arrays and kits for detecting and analyzing biomolecules
CA2382436C (en) 1999-08-30 2011-05-17 Illumina, Inc. Methods for improving signal detection from an array
US6770441B2 (en) 2000-02-10 2004-08-03 Illumina, Inc. Array compositions and methods of making same
AU7299301A (en) 2000-06-21 2002-01-02 Bioarray Solutions Ltd Multianalyte molecular analysis using application-specific random particle arrays
JP4361271B2 (ja) 2000-10-10 2009-11-11 バイオトローブ・インコーポレイテツド アッセイ、合成、および保存用の器具、ならびに、その作製、使用、および操作の方法
US6482936B1 (en) 2001-04-17 2002-11-19 Pe Corporation (Ny) Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof
US6780602B2 (en) 2001-11-01 2004-08-24 Microbiosystems, Limited Partnership Taxonomic identification of pathogenic microorganisms and their toxic proteins
WO2003102589A1 (en) 2002-04-08 2003-12-11 Bioinfra Inc. Method and system for analysis of cancer biomarkers using proteome image mining
US7718072B2 (en) 2002-04-26 2010-05-18 Abbott Laboratories Structure and method for handling magnetic particles in biological assays
US7375234B2 (en) 2002-05-30 2008-05-20 The Scripps Research Institute Copper-catalysed ligation of azides and acetylenes
US20040153249A1 (en) 2002-08-06 2004-08-05 The Johns Hopkins University System, software and methods for biomarker identification
DE10247896B4 (de) 2002-10-14 2007-01-18 Bruker Daltonik Gmbh Mehrdimensionale Trennung von Biosubstanzgemischen für massenspektrometrische Analysen
US7695738B2 (en) 2003-02-19 2010-04-13 Academia Sinica Carbohydrate encapsulated nanoparticles
US7425700B2 (en) 2003-05-22 2008-09-16 Stults John T Systems and methods for discovery and analysis of markers
US8574590B2 (en) 2003-07-30 2013-11-05 Integral Molecular, Inc. Lipoparticles comprising proteins, methods of making, and using the same
US20040106131A1 (en) 2003-08-18 2004-06-03 Swapan Roy Compositions and methods for proteomic investigations
EP1692298A4 (en) 2003-10-28 2008-08-13 Bioarray Solutions Ltd OPTIMIZATION OF GENE EXPRESSION ANALYSIS USING IMMOBILIZED CATCHES
EP1580559B1 (en) 2004-03-23 2013-12-25 Bio-Rad Laboratories, Inc. Methods for reducing the variance between analyte concentrations taken from complex sample mixtures
US9488655B2 (en) 2004-07-14 2016-11-08 The Regents Of The University Of California Biomarkers for detection of early- and late-stage endometrial cancer
WO2006032044A2 (en) 2004-09-15 2006-03-23 Microchip Biotechnologies, Inc. Microfluidic devices
DE102004051785B4 (de) 2004-10-25 2008-04-24 Bruker Daltonik Gmbh Proteinprofile mit Luft-MALDI
WO2006076612A2 (en) 2005-01-14 2006-07-20 Cabot Corporation A process for manufacturing application specific printable circuits (aspc’s) and other custom electronic devices
US8288169B2 (en) 2005-01-21 2012-10-16 Argylla Technologies Surface mediated self-assembly of nanoparticles
US9002652B1 (en) 2005-01-27 2015-04-07 Institute For Systems Biology Methods for identifying and using organ-specific proteins in blood
GB0514910D0 (en) 2005-07-20 2005-08-24 Solexa Ltd Method for sequencing a polynucleotide template
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
WO2007120248A2 (en) 2005-12-20 2007-10-25 The Ohio State University Research Foundation Nanoporous substrates for analytical methods
US9347945B2 (en) 2005-12-22 2016-05-24 Abbott Molecular Inc. Methods and marker combinations for screening for predisposition to lung cancer
EP3147665A1 (en) 2005-12-22 2017-03-29 Abbott Molecular Inc. Methods and marker combinations for screening for predisposition to lung cancer
US20070224644A1 (en) 2006-01-27 2007-09-27 Liotta Lance A Ocular fluid markers
JP5063616B2 (ja) 2006-02-03 2012-10-31 インテジェニックス インコーポレイテッド マイクロ流体デバイス
EP1987159B2 (en) 2006-02-08 2020-08-12 Illumina Cambridge Limited Method for sequencing a polynucleotide template
US7787681B2 (en) 2006-08-25 2010-08-31 The Trustees Of Columbia University In The City Of New York Systems and methods for robotic transport
US7815803B2 (en) 2007-06-14 2010-10-19 Roche Diagnostics Operations, Inc. Preparation of samples for LC-MS/MS using magnetic particles
WO2009006439A1 (en) 2007-06-29 2009-01-08 Correlogic Systems, Inc. Predictive markers for ovarian cancer
EP2207030A4 (en) 2007-10-05 2010-12-08 Univ Hokkaido DEVICE FOR AUTOMATIC PRE-TREATMENT OF A SUGAR CHAIN
ES2448426T3 (es) 2007-10-12 2014-03-13 Pronota Nv Uso de aptámeros en proteómica
CA2703478C (en) 2007-10-29 2015-07-07 Csir Emulsion-derived particles
US8021891B2 (en) 2007-11-28 2011-09-20 University Of Massachusetts Methods and compositions for protein detection using nanoparticle-fluorescent polymer complexes
US8796184B2 (en) 2008-03-28 2014-08-05 Sentilus, Inc. Detection assay devices and methods of making and using the same
KR101039629B1 (ko) 2008-05-22 2011-06-08 성균관대학교산학협력단 생체물질의 검출방법, 생체물질 검출용 칩의 제조방법 및생물질 검출용 칩
WO2010042555A2 (en) 2008-10-06 2010-04-15 The Brigham And Women's Hospital, Inc. Particles with multiple functionalized surface domains
WO2010078601A1 (en) 2009-01-05 2010-07-08 The Regents Of The University Of California High throughput biomolecule separation and analysis
US20110306514A1 (en) 2009-01-14 2011-12-15 United States Department of Health and Human Services Ratio based biomarkers and methods of use thereof
EP2401619A1 (en) 2009-02-26 2012-01-04 University College Dublin National University Of Ireland, Dublin A method for the selective concentration of a specific low abundance biomolecule
US20120135446A1 (en) * 2009-03-04 2012-05-31 Maine Institute For Human Genetics & Health, Inc Microfluidic Device and Related Methods
US20120190574A1 (en) 2009-06-19 2012-07-26 The Arizona Board of Regents, A body Corporate of the State of Arizona for and on behalf of Arizona Compound Arrays for Sample Profiling
EP2494364A1 (en) 2009-10-29 2012-09-05 Tethys Bioscience, Inc. Protein and lipid biomarkers providing consistent improvement to the prediction of type 2 diabetes
US9910040B2 (en) 2012-07-09 2018-03-06 Sevident, Inc. Molecular nets comprising capture agents and linking agents
US9005994B2 (en) 2010-01-14 2015-04-14 University Of Central Florida Research Foundation, Inc. Methods for biomolecule and biomolecule complex (BMC) detection and analysis and the use of such for research and medical diagnosis
JP6114035B2 (ja) 2010-02-10 2017-04-12 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 肺癌検出用唾液バイオマーカー
US9149432B2 (en) 2010-03-19 2015-10-06 Massachusetts Institute Of Technology Lipid vesicle compositions and methods of use
US20120171694A1 (en) 2010-07-30 2012-07-05 Vermillion, Inc. Predictive markers and biomarker panels for ovarian cancer
WO2012031205A2 (en) 2010-09-03 2012-03-08 The Brigham And Women's Hospital, Inc. Lipid-polymer hybrid particles
WO2012050920A1 (en) 2010-09-29 2012-04-19 Illumina, Inc. Compositions and methods for sequencing nucleic acids
US9329176B2 (en) 2010-11-18 2016-05-03 Academia Sinica Glycopeptide-functionalized nanoparticles arrays for capturing and detecting biomolecules
CN103703143B (zh) 2011-01-31 2016-12-14 爱普瑞斯生物公司 鉴定细胞中的多个表位的方法
GB201103726D0 (en) 2011-03-04 2011-04-20 Immunovia Ab Method, array and use thereof
JP2014526032A (ja) 2011-06-07 2014-10-02 カリス ライフ サイエンシズ ルクセンブルク ホールディングス エス．アー．エール．エル． 癌に対する循環バイオマーカー
US9624524B2 (en) 2011-06-15 2017-04-18 Massachusetts Institute Of Technology In vivo proteomic mapping
US20130058923A1 (en) 2011-08-03 2013-03-07 Qun Huo Biomolecular interactions and interaction products as biomarkers for detection, diagnosis, prognosis and predicting therapeutic responses of human diseases
CN103874770A (zh) 2011-08-08 2014-06-18 卡里斯生命科学卢森堡控股有限责任公司 生物标志物组合物和方法
PL2893040T3 (pl) 2012-09-04 2019-05-31 Guardant Health Inc Sposoby wykrywania rzadkich mutacji i wariantu liczby kopii
US10876152B2 (en) 2012-09-04 2020-12-29 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
CN105229164B (zh) 2013-03-15 2019-02-12 爱科谱迅病理研究公司 指示癌症疗法的srm测定
WO2014176435A2 (en) 2013-04-25 2014-10-30 Bergo Vladislav B Microarray compositions and methods of their use
WO2015099985A2 (en) 2013-12-23 2015-07-02 The Brigham And Women's Hospital, Inc. Cationic materials and formulations for drug delivery
US9594085B2 (en) 2014-02-03 2017-03-14 Integrated Diagnostics, Inc. Integrated quantification method for protein measurements in clinical proteomics
DK3102612T3 (da) 2014-02-07 2024-10-28 European Molecular Biology Laboratory Proteomisk prøveforberedelse ved anvendelse af paramagnetiske kugler
CN107073132B (zh) 2014-10-06 2021-08-27 梅约医学教育与研究基金会 载体-抗体组合物及其制备和使用方法
US10272050B2 (en) 2014-10-14 2019-04-30 The Brigham And Women's Hospital, Inc. Nanoparticles and methods of use
WO2016109452A1 (en) 2014-12-31 2016-07-07 Guardant Health , Inc. Detection and treatment of disease exhibiting disease cell heterogeneity and systems and methods for communicating test results
EP3259371B1 (en) * 2015-02-19 2020-09-02 Becton, Dickinson and Company High-throughput single-cell analysis combining proteomic and genomic information
US20180284125A1 (en) 2015-03-11 2018-10-04 The Broad Institute, Inc. Proteomic analysis with nucleic acid identifiers
US10900975B2 (en) 2015-05-12 2021-01-26 Arizona Board Of Regents On Behalf Of Arizona State University Systems and methods of epitope binning and antibody profiling
WO2017091631A1 (en) 2015-11-23 2017-06-01 Massachusetts Institute Of Technology Protein corona phase molecular recognition
US20180361000A1 (en) 2015-12-11 2018-12-20 The General Hospital Corporation Dextran nanoparticles for macrophage specific imaging and therapy
TWI760319B (zh) 2015-12-30 2022-04-11 杏國新藥股份有限公司 乳癌治療
WO2017173453A1 (en) 2016-04-01 2017-10-05 The Brigham And Women's Hospital, Inc. Stimuli-responsive nanoparticles for biomedical applications
CN109416926A (zh) 2016-04-11 2019-03-01 迪森德克斯公司 质谱数据分析工作流程
GB201615128D0 (en) 2016-09-06 2016-10-19 Univ Manchester Methods
JP2020514746A (ja) 2016-12-01 2020-05-21 ノーティラス バイオテクノロジー インコーポレイテッド タンパク質をアッセイする方法
WO2018112470A1 (en) 2016-12-16 2018-06-21 The Brigham And Women's Hospital, Inc. Co-delivery of nucleic acids for simultaneous suppression and expression of target genes
ES2993503T3 (en) 2016-12-16 2025-01-02 Brigham & Womens Hospital Inc System and method for protein corona sensor array for early detection of diseases
US20210072255A1 (en) 2016-12-16 2021-03-11 The Brigham And Women's Hospital, Inc. System and method for protein corona sensor array for early detection of diseases
US11009411B2 (en) 2017-08-14 2021-05-18 Sentons Inc. Increasing sensitivity of a sensor using an encoded signal
CN109593835B (zh) 2017-09-29 2023-12-12 深圳华大基因股份有限公司 用于微量ffpe rna样本评估的方法、试剂盒及应用
CN112154230A (zh) 2017-10-23 2020-12-29 诺迪勒思生物科技公司 用于蛋白质鉴定的方法和系统
WO2019084158A1 (en) 2017-10-26 2019-05-02 Ultima Genomics, Inc. METHODS AND SYSTEMS FOR SEQUENCE CALL
WO2019089846A1 (en) 2017-10-31 2019-05-09 Encodia, Inc. Methods and compositions for polypeptide analysis
WO2019099908A1 (en) * 2017-11-17 2019-05-23 10X Genomics, Inc. Methods and systems for associating physical and genetic properties of biological particles
WO2019108851A1 (en) 2017-11-30 2019-06-06 10X Genomics, Inc. Systems and methods for nucleic acid preparation and analysis
EP3502708B1 (en) 2017-12-21 2023-09-27 Tecan Trading AG Monitoring a laboratory automation device via a simulation model
CA3086915A1 (en) 2017-12-29 2019-07-04 Sujal M. Patel Decoding approaches for protein identification
GB2590185B (en) 2018-04-23 2022-09-28 Seer Inc Systems and methods for complex biomolecule sampling and biomarker discovery
BR112021001247A2 (pt) 2018-07-26 2021-04-27 Lexent Bio, Inc. sequenciamento múltiplo usando uma única célula de fluxo
MX2021002333A (es) 2018-08-30 2021-04-28 Univ Montreal Metodo basado en proteogenomica para identificar antigenos especificos de tumores.
CA3115991A1 (en) 2018-10-12 2020-04-16 Human Longevity, Inc. Multi-omic search engine for integrative analysis of cancer genomic and clinical data
CN113412519B (zh) 2019-02-11 2024-05-21 旗舰开拓创新六世公司 机器学习引导的多肽分析
JP7518852B2 (ja) 2019-03-26 2024-07-18 シアー， インコーポレイテッド 生物流体からのタンパク質コロナ分析のための組成物、方法およびシステム、ならびにそれらの使用
GB2606810A (en) 2019-08-05 2022-11-23 Seer Inc Systems and methods for sample preparation, data generation, and protein corona analysis
WO2021030460A1 (en) 2019-08-12 2021-02-18 Baylor College Of Medicine Proteogenomic methods for diagnosing cancer
WO2021087407A1 (en) 2019-11-02 2021-05-06 Seer, Inc. Systems for protein corona analysis
EP3901956A1 (en) 2020-04-21 2021-10-27 ETH Zürich Methods of determining correspondences between biological properties of cells
US20230212647A1 (en) 2020-05-29 2023-07-06 Seer, Inc. Systems and methods for rapid identification of proteins
GB202010922D0 (en) 2020-07-15 2020-08-26 Univ London Queen Mary Method
US20230324401A1 (en) 2020-07-20 2023-10-12 Seer, Inc. Particles and methods of assaying
US20220036969A1 (en) 2020-07-30 2022-02-03 Frontier Medicines Corporation Processing biophysical screening data and identifying and characterizing protein sites for drug discovery
GB2597997A (en) 2020-08-14 2022-02-16 Victoria Yates Emma Method of identifying the presence and/or concentration and/or amount of proteins or proteomes
DE112021004478T5 (de) 2020-08-25 2023-09-14 Seer, Inc. Zusammensetzungen und verfahren zur bestimmung von proteinen und nukleinsäuren
US20220260559A1 (en) 2020-11-04 2022-08-18 Seer, Inc. Biomarkers for diagnosing alzheimer's disease
US12531221B2 (en) 2020-11-17 2026-01-20 MOBILion Systems, Inc. Systems and method for image and/or video processing of mass spectrometry data
WO2022182989A1 (en) 2021-02-26 2022-09-01 Seer, Inc. Apparatus for biomolecule assay
WO2022232610A2 (en) 2021-04-29 2022-11-03 Seer, Inc. Peptide decorated nanoparticles for enrichment of specific protein subsets
US20240280558A1 (en) 2021-07-13 2024-08-22 Seer, Inc. Systems and methods for processing mass spectrometry datasets
US20230160882A1 (en) 2021-08-24 2023-05-25 Seer, Inc. Compositions and methods for low-volume biomolecule assays
EP4460829A4 (en) 2022-01-07 2026-01-14 Seer Inc Peptide-focused analyses
EP4466538A4 (en) 2022-01-20 2026-01-14 Seer Inc PARTICLES AND ASSAY METHODS
US20230253113A1 (en) 2022-02-04 2023-08-10 Seer, Inc. Systems and methods for creating biomolecule embeddings
WO2023159083A2 (en) 2022-02-15 2023-08-24 Seer, Inc. Systems and methods for analyzing omics data
US12437980B2 (en) 2022-05-20 2025-10-07 Sapient Bioanalytics, Llc Mass spectrometry retrieving of stray samples
WO2024040189A1 (en) 2022-08-18 2024-02-22 Seer, Inc. Methods for using a machine learning algorithm for omic analysis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020096631A2 (en) * 2018-11-07 2020-05-14 Seer, Inc. Compositions, methods and systems for protein corona analysis and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PROTEOMICS, vol. 14, JPN6025038380, 2014, pages 2742 - 2749, ISSN: 0005689531 *

Also Published As

Publication number Publication date
IL300826A (en) 2023-04-01
US20230408503A1 (en) 2023-12-21
US20250244336A1 (en) 2025-07-31
AU2021333661A1 (en) 2023-03-23
CN116529393A (zh) 2023-08-01
KR20230079044A (ko) 2023-06-05
CA3190719A1 (en) 2022-03-03
US12276668B2 (en) 2025-04-15
WO2022046804A2 (en) 2022-03-03
CN116529393A8 (zh) 2023-10-27
DE112021004478T5 (de) 2023-09-14
WO2022046804A3 (en) 2022-04-07
EP4204580A4 (en) 2025-03-19
EP4204580A2 (en) 2023-07-05

Similar Documents

Publication Publication Date Title
US12276668B2 (en) Compositions and methods for assaying proteins and nucleic acids
JP7803989B2 (ja) サンプル調製、データ生成、タンパク質コロナ分析のためのシステムおよび方法
US20230160882A1 (en) Compositions and methods for low-volume biomolecule assays
JP2025522362A (ja) マルチオミクス評価
US20240125795A1 (en) Apparatus for biomolecule assay
US20230212647A1 (en) Systems and methods for rapid identification of proteins
Cayer et al. Mission critical: the need for proteomics in the era of next-generation sequencing and precision medicine
JP2024534992A (ja) 生体分子の増強された検出および定量
US20250157570A1 (en) Systems and methods for analyzing omics data
Suravajhala et al. Combining aptamers and in silico interaction studies to decipher the function of hypothetical proteins
HK40124213A (en) Multi-omics assessment
WO2026107397A1 (en) Characterization of the epigenetic landscape in complex fluids
CN117202991A (zh) 用于生物分子测定的装置
Donovan et al. Peptide-centric analyses of human plasma enable increased resolution of biological insights into non-small cell

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240826

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240826

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250820

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250917

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251216

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260317

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260612